Title

A Crossover Study of the Acute Effects of Olanzapine in Healthy Volunteers
A Double-blind, Placebo-controlled, Crossover Study Examining the Acute Effects of Olanzapine on Plasma Leptin, Glucose Tolerance and Free Fatty Acids in Healthy Volunteers
  • Phase

    N/A
  • Study Type

    Interventional
  • Intervention/Treatment

    olanzapine ...
  • Study Participants

    15
The purpose of this clinical research study is to examine the acute hormonal and metabolic effects of the drug olanzapine, as well as appetite effects, in healthy volunteers. The hypotheses to be tested are that: (1) Olanzapine rapidly attenuates plasma leptin and (2) rapidly alters glucose tolerance in healthy volunteers. These questions will be answered by having volunteers undergo two glucose tolerance tests in a crossover study design.
Study Started
Aug 31
2008
Primary Completion
Dec 31
2010
Study Completion
May 31
2011
Results Posted
Jul 14
2014
Estimate
Last Update
Jul 14
2014
Estimate

Drug Olanzapine 10 mg po qhs for 3 days

(1) 10 mg tablets administered orally before bed for three consecutive evenings (Total Dose = 30 mg, 3 tablets)

  • Other names: Zyprexa

Drug Placebo

(1) placebo tablets administered orally before bed for three consecutive evenings (Total Dose = 3 tablets)

  • Other names: Sugar pill

Placebo Placebo Comparator

Placebo

Olanzapine Experimental

Olanzapine 10mg po daily x 3 days

Criteria

Inclusion Criteria:

Healthy Volunteer
Body Mass Index of 18.5-25 kilograms per square meter
Must be able to swallow tablets
Able to give informed consent

Exclusion Criteria:

Any DSM-IV TR Axis I psychiatric disorder (except nicotine dependence)
Presence of any medical disorder that may confound the assessment of relevant biologic measures, including: significant organ system dysfunction, metabolic diseases, type 1 diabetes mellitus, type 2 diabetes mellitus, pregnancy, endocrine disease, coagulopathy, clinically significant anemia, or acute infection
Subjects who have taken any antipsychotic medication within the last 6 months
Personal or family history of seizures and/or cardiac arrhythmias

Summary

Placebo

Olanzapine

All Events

Event Type Organ System Event Term

Plasma Leptin

Leptin following placebo or olanzapine treatment

Placebo

6.8
ng/ml (Mean)
Standard Deviation: 1.3

Olanzapine

8.4
ng/ml (Mean)
Standard Deviation: 1.7

Oral Glucose Tolerance

Oral Glucose Tolerance

Placebo

2808.0
min*mg/dl (Mean)
Standard Deviation: 474

Olanzapine

3984.0
min*mg/dl (Mean)
Standard Deviation: 444

Plasma Free Fatty Acid

Plasma Free Fatty Acid

Placebo

0.38
mM (Mean)
Standard Deviation: 0.06

Olanzapine

0.26
mM (Mean)
Standard Deviation: 0.04

HDL Cholesterol

HDL Cholesterol

Placebo

54.2
mg/dl (Mean)
Standard Deviation: 4.7

Olanzapine

48.9
mg/dl (Mean)
Standard Deviation: 4.3

Triglycerides

Triglycerides

Placebo

88.9
mg/dl (Mean)
Standard Deviation: 10.1

Olanzapine

108.2
mg/dl (Mean)
Standard Deviation: 11.6

LDL Cholesterol

LDL Cholesterol

Placebo

82.7
mg/dl (Mean)
Standard Deviation: 6.6

Olanzapine

81.7
mg/dl (Mean)
Standard Deviation: 7.8

Total Cholesterol

Total Cholesterol

Placebo

156.8
mg/dl (Mean)
Standard Deviation: 9.1

Olanzapine

152.6
mg/dl (Mean)
Standard Deviation: 10.1

Body Weight

Body Weight

Placebo

68.2
kg (Mean)
Standard Error: 2.9

Olanzapine

68.9
kg (Mean)
Standard Error: 3.0

BMI

BMI

Placebo

23.0
kg / m2 (Mean)
Standard Error: 0.5

Olanzapine

23.0
kg / m2 (Mean)
Standard Error: 0.6

Heart Rate

Heart Rate

Placebo

69.9
beats per minute (Mean)
Standard Error: 2.6

Olanzapine

67.6
beats per minute (Mean)
Standard Error: 3.5

Systolic Blood Pressure

Systolic Blood Pressure

Placebo

113.3
mmHg (Mean)
Standard Error: 2.8

Olanzapine

111.7
mmHg (Mean)
Standard Error: 3.1

Diastolic Blood Pressure

Diastolic Blood Pressure

Placebo

68.3
mmHg (Mean)
Standard Error: 2.0

Olanzapine

69.5
mmHg (Mean)
Standard Error: 1.8

Age, Continuous

26.6
years (Mean)
Standard Deviation: 0.5

Age, Categorical

Region of Enrollment

Sex: Female, Male

Overall Study

Placebo / Olanzapine